NUDT22

Across TCGA pan-cancer cohorts, NUDT22 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated NUDT22 data layer compared with 23 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher NUDT22 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated NUDT22 expression acts as an unfavorable survival marker, although some lineages such as LUAD and HNSC show a favorable association.

LUAD, HNSC, and UCEC are the cancer types where NUDT22 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	II,III,IV	0.916	0.539	.011	10	view →
HNSC	OS	Median	IV	0.899	0.570	.011	6	view →
UCEC	OS	Median	II,III,IV	0.429	1.000	.044	4	view →
LSCC	OS	Median	II,III,IV	0.872	1.000	.037	2	view →
CCRCC	OS	Median	III,IV	0.694	0.916	.037	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

NUDT22–LUAD (OS)

Open the LUAD breakdown →